---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-005368"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T10:53:02.822711+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protagenic shareholders approve reverse stock split at ratio 1:10 to 1:20

## Summary
- Special Meeting held April 18, 2025; 4,049,963 shares present out of 7,241,443 entitled.
- Reverse split proposal passed: 3,560,865 for, 333,824 against, 155,274 abstain.
- Board authorized to choose exact ratio between 1:10 and 1:20 and timing before Jan 31, 2026.
- Adjournment proposal also approved: 3,552,086 for, 336,677 against, 161,200 abstain.

## SEC filing metadata
- accession: 0001641172-25-005368
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000164117225005368/0001641172-25-005368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000164117225005368/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-005368
- JSON: https://secwatch.observer/filing/0001641172-25-005368.json
- Plain text: https://secwatch.observer/filing/0001641172-25-005368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.